$13.50
0.88% day before yesterday
NYSE, Dec 27, 10:10 pm CET
ISIN
US87911K1007
Symbol
HQL

Tekla Life Sciences Investors Stock price

$13.50
-0.63 4.46% 1M
-0.67 4.73% 6M
+0.04 0.30% YTD
-0.10 0.74% 1Y
-6.14 31.26% 3Y
-4.13 23.44% 5Y
-10.85 44.56% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.12 0.88%
ISIN
US87911K1007
Symbol
HQL
Sector

Key metrics

Market capitalization $378.83m
Enterprise Value $361.60m
EV/Sales (TTM) EV/Sales 10.06
P/S ratio (TTM) P/S ratio 10.54
Dividend yield 13.78%
Last dividend (FY24) $1.86
Revenue growth (TTM) Revenue growth -8.75%
Revenue (TTM) Revenue $35.94m
EBIT (operating result TTM) EBIT $85.30m
EPS (TTM) EPS $3.09
Show more

Is Tekla Life Sciences Investors a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Financial data from Tekla Life Sciences Investors

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Sep '24
+/-
%
36 36
9% 9%
100%
- Direct Costs 5.36 5.36
2% 2%
15%
31 31
10% 10%
85%
- Selling and Administrative Expenses - -
- Research and Development Expense - -
-
-
85 85
282% 282%
237%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 85 85
282% 282%
237%
Net Profit 85 85
282% 282%
237%

In millions USD.

Don't miss a Thing! We will send you all news about Tekla Life Sciences Investors directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tekla Life Sciences Investors Stock News

Positive
Seeking Alpha
about one month ago
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs wi...
Positive
Seeking Alpha
2 months ago
For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid tr...
Positive
Seeking Alpha
3 months ago
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs wi...
More Tekla Life Sciences Investors News

Company Profile

Tekla Life Sciences Investors operates as a closed-end investment fund or Investment trust. The firm engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.

Head office United States
CEO Dan Omstead
Founded 1992
Website www.teklacap.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today